FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077122875> ?p ?o ?g. }

• W2077122875 endingPage "1216" @default.
• W2077122875 startingPage "1209" @default.
• W2077122875 abstract "Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists are increasingly used in patients with diabetes, and some studies have suggested a beneficial effect on organ fibrosis, but their effects on dermal cell growth and extracellular matrix (ECM) turnover are unknown. To investigate the effect of the PPAR-gamma agonist troglitazone on cell growth and matrix production in human dermal fibroblasts (HDF), HDF were cultured and grown in a different concentration of troglitazone. PPAR-gamma expression and matrix production were measured in HDF in the presence of troglitazone. The mRNA expressions of TGF-beta1, collagen I (Col I) and fibronectin (FN) were determined by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR). The protein of transforming growth factor-beta1 (TGF-beta1) was determined by enzyme-linked immunosorbent assay (ELISA) and proteins of Col I and FN were determined by Western blotting. The mRNA expression of TGF-beta1, Col I and FN were significantly decreased in HDF in 15-30 micromol l(-1) troglitazone compared to the control group with Dulbecco's modified Eagle's medium (P<0.01). An obvious decrease of TGF-beta1 protein was found in troglitazone-treated groups as compared to the control group (P<0.05). Exposure of HDF to troglitazone reduced col I secretion (P<0.05), and fibronectin secretion (P<0.05). This study suggests that PPAR-gamma agonist will provide a novel approach with therapeutic potential in dermal fibrosis, such as hypertrophic scar, keloid and so on." @default.
• W2077122875 created "2016-06-24" @default.
• W2077122875 creator A5003674196 @default.
• W2077122875 creator A5015010876 @default.
• W2077122875 creator A5015674482 @default.
• W2077122875 creator A5023386931 @default.
• W2077122875 creator A5030038857 @default.
• W2077122875 creator A5040242042 @default.
• W2077122875 creator A5048192991 @default.
• W2077122875 creator A5050259330 @default.
• W2077122875 creator A5063675200 @default.
• W2077122875 creator A5068714954 @default.
• W2077122875 creator A5071515443 @default.
• W2077122875 creator A5082575697 @default.
• W2077122875 creator A5085582095 @default.
• W2077122875 creator A5088438244 @default.
• W2077122875 date "2010-07-01" @default.
• W2077122875 modified "2023-10-16" @default.
• W2077122875 title "Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts" @default.
• W2077122875 cites W1508850474 @default.
• W2077122875 cites W1966346645 @default.
• W2077122875 cites W1970779494 @default.
• W2077122875 cites W1974083851 @default.
• W2077122875 cites W1996764438 @default.
• W2077122875 cites W2002670032 @default.
• W2077122875 cites W2015615071 @default.
• W2077122875 cites W2025657436 @default.
• W2077122875 cites W2031054297 @default.
• W2077122875 cites W2032150705 @default.
• W2077122875 cites W2048055673 @default.
• W2077122875 cites W2056226437 @default.
• W2077122875 cites W2060815067 @default.
• W2077122875 cites W2084096026 @default.
• W2077122875 cites W2088123830 @default.
• W2077122875 cites W2096541753 @default.
• W2077122875 cites W2128573668 @default.
• W2077122875 cites W2159347821 @default.
• W2077122875 doi "https://doi.org/10.1016/j.bjps.2009.06.032" @default.
• W2077122875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19617014" @default.
• W2077122875 hasPublicationYear "2010" @default.
• W2077122875 type Work @default.
• W2077122875 sameAs 2077122875 @default.
• W2077122875 citedByCount "27" @default.
• W2077122875 countsByYear W20771228752012 @default.
• W2077122875 countsByYear W20771228752013 @default.
• W2077122875 countsByYear W20771228752014 @default.
• W2077122875 countsByYear W20771228752015 @default.
• W2077122875 countsByYear W20771228752016 @default.
• W2077122875 countsByYear W20771228752017 @default.
• W2077122875 countsByYear W20771228752019 @default.
• W2077122875 countsByYear W20771228752021 @default.
• W2077122875 countsByYear W20771228752022 @default.
• W2077122875 countsByYear W20771228752023 @default.
• W2077122875 crossrefType "journal-article" @default.
• W2077122875 hasAuthorship W2077122875A5003674196 @default.
• W2077122875 hasAuthorship W2077122875A5015010876 @default.
• W2077122875 hasAuthorship W2077122875A5015674482 @default.
• W2077122875 hasAuthorship W2077122875A5023386931 @default.
• W2077122875 hasAuthorship W2077122875A5030038857 @default.
• W2077122875 hasAuthorship W2077122875A5040242042 @default.
• W2077122875 hasAuthorship W2077122875A5048192991 @default.
• W2077122875 hasAuthorship W2077122875A5050259330 @default.
• W2077122875 hasAuthorship W2077122875A5063675200 @default.
• W2077122875 hasAuthorship W2077122875A5068714954 @default.
• W2077122875 hasAuthorship W2077122875A5071515443 @default.
• W2077122875 hasAuthorship W2077122875A5082575697 @default.
• W2077122875 hasAuthorship W2077122875A5085582095 @default.
• W2077122875 hasAuthorship W2077122875A5088438244 @default.
• W2077122875 hasConcept C118131993 @default.
• W2077122875 hasConcept C126322002 @default.
• W2077122875 hasConcept C134018914 @default.
• W2077122875 hasConcept C170493617 @default.
• W2077122875 hasConcept C185592680 @default.
• W2077122875 hasConcept C187345961 @default.
• W2077122875 hasConcept C189165786 @default.
• W2077122875 hasConcept C2775960820 @default.
• W2077122875 hasConcept C2778150266 @default.
• W2077122875 hasConcept C2778229498 @default.
• W2077122875 hasConcept C2778938600 @default.
• W2077122875 hasConcept C55493867 @default.
• W2077122875 hasConcept C71924100 @default.
• W2077122875 hasConcept C86492073 @default.
• W2077122875 hasConceptScore W2077122875C118131993 @default.
• W2077122875 hasConceptScore W2077122875C126322002 @default.
• W2077122875 hasConceptScore W2077122875C134018914 @default.
• W2077122875 hasConceptScore W2077122875C170493617 @default.
• W2077122875 hasConceptScore W2077122875C185592680 @default.
• W2077122875 hasConceptScore W2077122875C187345961 @default.
• W2077122875 hasConceptScore W2077122875C189165786 @default.
• W2077122875 hasConceptScore W2077122875C2775960820 @default.
• W2077122875 hasConceptScore W2077122875C2778150266 @default.
• W2077122875 hasConceptScore W2077122875C2778229498 @default.
• W2077122875 hasConceptScore W2077122875C2778938600 @default.
• W2077122875 hasConceptScore W2077122875C55493867 @default.
• W2077122875 hasConceptScore W2077122875C71924100 @default.
• W2077122875 hasConceptScore W2077122875C86492073 @default.
• W2077122875 hasIssue "7" @default.
• W2077122875 hasLocation W20771228751 @default.

• next